Sotagliflozin: an insight into the first dual SGLT inhibitor now approved for heart failure

Ir J Med Sci. 2024 Apr;193(2):669-670. doi: 10.1007/s11845-023-03474-8. Epub 2023 Jul 31.

Authors

Muhammad Affan¹, Marrium S Dar²

Affiliations

¹ Department of Internal Medicine, Jinnah Sindh Medical University, Karachi, Pakistan. [email protected].
² Department of Internal Medicine, Jinnah Sindh Medical University, Karachi, Pakistan.

PMID: 37523069
DOI: 10.1007/s11845-023-03474-8

No abstract available

Publication types

Letter

MeSH terms

Diabetes Mellitus, Type 2*
Glycosides / pharmacology
Glycosides / therapeutic use
Heart Failure* / drug therapy
Humans
Hypoglycemic Agents / therapeutic use

Substances

(2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(methylthio)tetrahydro-2H-pyran-3,4,5-triol
Glycosides
Hypoglycemic Agents